SGM-101 in Locally Advanced and Recurrent Rectal Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific
tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about
tumor location and extensiveness, which can be difficult to detect with conventional visual
and tactile feedback. Hence, this information could aid in intra-operative decision making
and therewith foster complete resection margins and less extensive surgery. Subsequently,
this may drastically improve patient care by improving oncologic outcome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Leiden University Medical Center
Collaborators:
Catharina Ziekenhuis Eindhoven Centre for Human Drug Research, Netherlands Erasmus Medical Center Medical Center Haaglanden Quest Medical Imaging Surgimab VU University Medical Center